即时询价 ×
* 必填项
请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。
Inquiry Online
×
* Required Fields.
Please complete the form below and we will contact you shortly.
Bulk Inquiry
×
* Required Fields.
Please complete the form below and we will contact you shortly.
CAS号 | 2173389-57-4 | 货号 | BCP49234 |
中文名 | Zilurgisertib | ||
英文名 | Zilurgisertib | ||
中文别名 | |||
英文别名 | INCB-000928; NBU-928;INCB000928; NBU928;INCB 000928; NBU 928; | ||
SMILES | C1COCCC1N2CC3CC3(C2)C4=CC=C(C=C4)C5=CC(=C(N=C5)N)C(=O)NC67CCC(CC6)(CC7)O | ||
化学名称 | |||
分子式 | C30H38N4O3 | 分子量 | 502.65 |
纯度 | 98% | 配送 | 惯例下常温包邮 |
产品描述 | Zilurgisertib is an inhibitor of activin A receptor type 1 (activin receptor-like kinase 2; ALK2; ALK-2; ACVR1; ACTR-I), with potential anti-anemic and ossification suppressive activities. Upon administration, zilurgisertib targets, binds to and inhibits the activity of ALK-2. This prevents ALK2-mediated signaling and ALK2-mediated excessive bone morphogenetic protein (BMP) signaling. This may suppress heterotopic ossification (HO). As ALK-2 enhances the secretion of hepcidin, a peptide liver hormone and a key modulator of iron homeostasis, zilurgisertib is able to decrease hepcidin expression in the liver, thereby increasing and restoring plasma iron levels, enhancing erythropoiesis, and correcting anemia of chronic disease (ACD). ALK2, a serine/threonine receptor kinase and type I cell surface receptor for BMPs, is constitutively activated due to activating mutations in inflammatory conditions, various types of cancer, and in fibrodysplasia ossificans progressiva (FOP). Elevated serum hepcidin levels enhance storage of iron, reduce iron availability and causes iron deficiency anemia. |
相关产品推荐
查看更多 >Tags:Zilurgisertib 供应商,Zilurgisertib 购买,Zilurgisertib 生产,Zilurgisertib 批量,Zilurgisertib 供应,Zilurgisertib 订购,Zilurgisertib 采购